Research programme: Nav1.7 sodium channel openers - Xenon Pharmaceuticals
Alternative Names: Nav1.7 sodium channel openers - Xenon PharmaceuticalsLatest Information Update: 03 Jul 2024
At a glance
- Originator Xenon Pharmaceuticals
- Class Analgesics
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 03 Jul 2024 Preclinical trials in Pain in Canada (unspecified route), before July 2024 (Xenon Pharmaceuticals pipeline, July 2024)
- 03 Jul 2024 Xenon Pharmaceuticals plans to advance multiple candidates into IND-enabling studies in 2024 and 2025 (Xenon Pharmaceuticals pipeline, June 2024)
- 31 Dec 2023 Xenon Pharmaceuticals has patent protection for Nav1.7 sodium channel openers in US, before December 2023